How New FDA Approvals Make Cord Blood Transplants Viable for Adults

Cord blood transplants, once limited to children, are now a viable option for adults thanks to recent FDA approvals. Between 2023 and 2025, advancements in stem cell expansion technology, particularly through Omisirge (omidubicel-onlv), have addressed the challenge of insufficient cell counts for adults. Omisirge accelerates recovery, reduces infection risks, and expands treatment options for conditions like blood cancers and severe aplastic anemia. Key benefits include:

• Faster recovery: Neutrophil recovery in 12 days vs. 22 days with older methods.
• Lower infection rates: 39% vs. 60% within 100 days.
• Expanded eligibility: Adults now benefit from treatments previously restricted to children.

These approvals signal a major shift in stem cell therapy, offering new hope for adults battling blood and immune disorders.

FDA Approvals That Expanded Adult Cord Blood Transplants

Two pivotal FDA approvals have reshaped the use of cord blood transplants, making them a practical option for adults, not just children. Both approvals focus on Omisirge (omidubicel-onlv), a product developed by Gamida Cell Ltd. Omisirge uses nicotinamide (a form of vitamin B3) to increase the number of stem cells in cord blood units. This breakthrough addressed a long-standing issue: traditional cord blood units contained too few stem cells for patients over 110 pounds (around 50 kg). Here's how these approvals have transformed treatment options.

Omisirge Approval in 2023 for Blood Cancers

On April 17, 2023, the FDA approved Omisirge for patients aged 12 and older with blood cancers like AML, ALL, and MDS. This marked a major milestone as the first expanded cord blood product approved for transplantation.

The approval was based on Study P0501, a Phase 3 trial involving 125 patients (62 received Omisirge, 63 received standard cord blood). Results showed that 87% of Omisirge patients achieved neutrophil recovery, compared to 83% in the control group.

"The approval of Omisirge is a significant development in hematopoietic stem-cell transplantation. Adding Omisirge as a new donor source may help increase access to stem-cell transplant for patients from racially or ethnically diverse backgrounds who struggle to find a fully matched donor in the registry."

• Steven M. Devine, MD, Chief Medical Officer of the National Marrow Donor Program/Be The Match

Before Omisirge, oncologists often had to rely on half-matched bone marrow donors due to limited cell counts in cord blood. This approval expanded donor options significantly, paving the way for further advancements, including the 2025 approval.

2025 Approval for Severe Aplastic Anemia

On December 8, 2025, the FDA broadened Omisirge's use to include severe aplastic anemia (SAA) for patients aged 6 and older. SAA is a rare condition where the bone marrow fails to produce enough blood cells. This marked the first cellular therapy approved specifically for SAA.

The expanded approval was supported by a Phase 1/2 study of 14 high-risk SAA patients who lacked compatible donors. Among them, 12 patients (85.7%) achieved early and sustained neutrophil engraftment, with a median recovery time of 11 days (ranging from 7 to 20 days). Other key outcomes included a 94% disease-free and overall survival rate, 86% transfusion independence, and no severe cases of acute or chronic graft-versus-host disease.

"This approval is revolutionary in the therapeutic landscape and fundamentally changes how we approach treatment for SAA, where earlier treatment has potential to alter one's life course."

• Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer and Director of the FDA's Center for Biologics Evaluation and Research

To ensure safety, the FDA required Gamida Cell to conduct a post-marketing observational study involving at least 24 patients, set for completion by 2031. This study aims to better understand the risk of autoimmune cytopenia, which occurred in 25% of SAA patients during trials. Patients receiving Omisirge for SAA are now monitored for at least two years after treatment.

These approvals have reshaped how blood disorders are treated in adults. Projections suggest that Omisirge could account for 20% to 25% of the roughly 10,000 allogeneic stem cell transplants performed annually in the U.S., offering new hope to thousands of patients.

Stem Cell Therapy Advances for Adults

Stem cell therapy for adults has made significant progress, thanks to FDA-approved innovations in stem cell expansion. These advancements tackle a long-standing issue: the limited number of stem cells available from a single cord blood unit, which has historically restricted its use primarily to children. Since stem cell doses are calculated based on body weight, adult patients often couldn't receive transplants due to insufficient cell counts. But new techniques have changed the game, offering hope to adult patients without suitable donors.

Nicotinamide Expansion Technology

One of the most promising advancements is the use of nicotinamide, a form of vitamin B3. By culturing cord blood stem cells with nicotinamide and cytokines over 21–24 days, scientists have achieved a 33-fold increase in CD34+ cells - the essential cells needed for successful engraftment. This process works by boosting renewal and DNA repair mechanisms while preventing premature differentiation of the cells.

What’s even more impressive is that these expanded cells are not just more numerous - they’re also more effective. This technology enhances their ability to migrate to the bone marrow and engraft successfully, enabling a single cord blood unit to meet the needs of an adult patient. Previously, adults often required two cord blood units or were excluded from treatment altogether. These breakthroughs are already being applied in FDA-approved therapies, transforming the landscape of stem cell transplants.

Improved Clinical Outcomes: Faster Recovery and Lower Infection Risk

Clinical trials show that expanded cord blood cells drastically shorten recovery times. Neutrophil recovery, a critical milestone in transplant success, occurs in just 12 days - much faster than with traditional methods. This quicker recovery period significantly reduces the risk of life-threatening bacterial and fungal infections, which are most likely to occur when blood counts are low.

"Compared to standard cord blood transplant, the reduction in recovery time translates into significant improvement in the safety profile of the transplant procedure. It's when their blood counts are low that patients are most vulnerable to infections, so by reducing that time to 11.5 days, we shorten that vulnerable period."

• Mitchell Horwitz, M.D., Professor of Medicine, Duke Cancer Institute

The benefits don’t stop there. Patients receiving expanded cord blood spent an average of 48 days in the hospital during the first 100 days post-transplant, compared to 61 days for those with traditional cord blood transplants. Infection rates dropped from 60% to 39%, and platelet recovery improved from 46 days to 34 days. Remarkably, expanded cord blood now engrafts faster than traditional bone marrow, with recovery times of 10–12 days versus 15–17 days. These improvements not only enhance safety and recovery but also expand treatment options for adults with blood disorders, reshaping how donor selection is approached.

What These Approvals Mean for Adults with Blood Disorders

More Treatment Options and Better Access

The FDA's recent approvals of Omisirge and Regenecyte mark a turning point for adults battling blood cancers and rare blood disorders. These therapies broaden donor options, removing the need for a perfect HLA match. Thanks to new expansion technology, a single cord blood unit can now supply enough stem cells for larger adult patients, eliminating the need for multiple units - a barrier that once limited treatment. Even better, these therapies are ready for immediate use.

The clinical data speaks volumes. For Regenecyte, 91% of patients achieved neutrophil recovery within 42 days, and 72% reached platelet recovery by day 100. Meanwhile, patients with severe aplastic anemia treated with Omisirge experienced an impressive 94% survival rate, with neutrophil recovery happening in just 8 days. These advancements go beyond overcoming old challenges - they offer ready-to-use solutions that are changing lives.

Patient Success Stories

The real-world impact of these therapies is undeniable. A clinical trial (NCT03173937) conducted by the National Institutes of Health enrolled 18 patients, ranging in age from 4 to 60, all suffering from severe aplastic anemia that hadn’t responded to standard immunosuppressive treatments. Led by Dr. Richard Childs, the study used omidubicel (Omisirge) and achieved a 94% survival rate, with a median neutrophil engraftment time of just 8 days.

"The results of this ongoing study are extremely encouraging and indicate a significant advancement in the treatment options for patients with a high unmet medical need."

• Dr. Richard Childs

This trial highlights the critical role of cord blood banking in delivering fast, life-saving treatments to patients in need.

Why Cord Blood Banking with Americord Registry Matters

How Americord Registry Supports FDA-Approved Treatments

Cord blood banking has become a game-changer, with the FDA approving treatments for over 80 conditions. Americord Registry ensures that families have access to high-quality stem cells for potential future medical needs. Private banking offers a genetic match for the baby and a 25% chance of a perfect match for siblings. Plus, transplants using cord blood from a family member have double the success rate compared to those using unrelated donors. Clinical trials have shown that rapid neutrophil recovery can happen in as little as 11 days, making quick access to compatible stem cells a critical factor in life-saving treatments.

Americord's dedication to quality is evident in their advanced storage methods.

CryoMaxx™ Processing and Storage Technology

Stem cell transplants for adults require higher cell counts than those for children, often needing at least 2.0 × 10⁷ cells per kilogram of body weight. Americord's CryoMaxx™ technology ensures maximum recovery of stem cells, with stored units maintaining approximately 90.64% total nucleated cell (TNC) recovery and 88.64% viability - even after 18 years of cryopreservation. This means the cells are preserved for long-term use without compromising their effectiveness.

What sets Americord apart is their 5-compartment storage system, which allows for multiple treatments from a single cord blood unit. This flexibility will become even more valuable as technologies like Omisirge advance. To back their commitment, Americord offers a $110,000 Cord Blood Quality Guarantee - the highest in the industry. As CEO Martin Smithmyer explains:

"With the confidence of the technologies and processes we are providing to families who want to store stem cells from their newborn... we are excited to offer the highest quality guarantee in the industry."

Making Informed Health Decisions for Your Family

The chances of needing a stem cell transplant by age 70 are about 1 in 217. Clinical trials are already investigating how cord blood could help treat conditions like Alzheimer's, autism, cerebral palsy, and long COVID, expanding its potential beyond current blood-related treatments.

Families should consider discussing cord blood banking with their healthcare provider at least three months before their due date. This ensures it can be included in the birth plan. To manage costs, many families use Flexible Spending Accounts (FSAs) or Health Savings Accounts (HSAs). Initial processing fees typically range from $1,500 to $3,000, with annual storage fees between $175 and $250. Opting for lifetime storage plans can cut costs by up to 69% compared to annual payments. These options allow families to plan ahead, giving them access to advanced treatments for serious health conditions down the road.

Conclusion

Recent FDA approvals for expanded cord blood products - like Omisirge in 2023 and 2025, and REGENECYTE in 2024 - have opened new doors for adult treatments. Thanks to advancements in expansion technologies using nicotinamide, stem cell counts now increase by 33-fold, addressing the previous challenge of limited cell counts in adults. These expanded therapies also speed up neutrophil recovery to just 8–10 days, compared to the 20–24 days seen with unmanipulated units. The result? Shorter hospital stays and a lower risk of infections.

The benefits of these therapies go beyond treating blood cancers. In 2025, an NIH clinical trial for severe aplastic anemia reported a 94% survival rate. Dr. Richard Childs, Assistant U.S. Surgeon General, highlighted the significance of these advancements:

"The approval of a therapy for patients who were lacking therapeutic options is a prime example of how NIH advances patient care and helps shape the future of medicine through the development of new therapeutics."

These advancements mean that stored stem cells can now be expanded to treat not just children but also adult family members. Meanwhile, over 3,000 studies worldwide are exploring stem cells for a variety of applications, promising even more possibilities in the future.

Americord Registry’s CryoMaxx™ processing technology plays a key role in preserving stem cell recovery and viability over the long term, ensuring compatibility with advanced expansion protocols. By securing cord blood with Americord Registry, families are taking an important step in preparing for future medical needs.

FAQs

Am I eligible for an expanded cord blood transplant like Omisirge?

If you're exploring treatment options for blood cancers, you might qualify for an expanded cord blood transplant, such as Omisirge. Thanks to recent FDA approvals, these transplants are now a possibility for adults. The key breakthrough is the increased availability of stem cells, which could enhance treatment outcomes for certain conditions.

Eligibility for this procedure depends on your overall health and specific medical factors. To find out if this could be a suitable option for you, talk to your healthcare provider. They can guide you through the details and help determine the best course of action.

What are the biggest risks and side effects of Omisirge for adults?

The primary risks and side effects of Omisirge in adults include delays in hematopoietic recovery, an increased risk of infections, and complications stemming from immune system suppression caused by high-dose chemotherapy or radiation used during conditioning. These are critical factors for patients undergoing this treatment to keep in mind.

How does banking cord blood with Americord help my family later?

Banking cord blood with Americord offers a meaningful way to support your family’s health in the future. Stem cells collected from your baby’s umbilical cord have the potential to treat more than 80 diseases, including various blood disorders and immune system deficiencies.

With recent FDA approvals, the use of cord blood has extended to adult treatments, opening doors to advanced therapies like enhanced transplants for adults. This makes storing cord blood a forward-thinking step to protect your family’s well-being for years to come.